Related Jobs
-
Senior Clinical Research Associate
Job Type: Permanent
Salary: SEK 444000.00 per annum
Location: Sweden -
CRA
Job Type: Permanent
Salary: DKK 35000.00 per annum
Location: Denmark
Heart failure risk drops 'a third' with new drug
04 Sep 2006
Clinical Research
Certain patients who have not previously suffered a heart attack are a third (31 per cent) less likely to when treated with Celacade, according to parent company Vasogen.
Over 2,400 patients are being studied under the Acclaim trial, which is looking at chronic heart failure and its prevention.
Working with the New York Heart Association's classification of heart failure, all the class II patients (those with mild symptoms and slight physical impairment) and those in classes II and III (moderate and severe symptoms) who had not had a previous heart attack were 31 per cent less at risk when treated.
Dr Guillermo Torre-Amione, lead researcher of the US arm of the Acclaim trial, said: "The Acclaim results provide compelling evidence that Celacade significantly reduces the risk of death and cardiovascular hospitalisation in an important group of heart failure patients that remain underserved by available therapies."
"These results provide a strong basis for targeting Celacade's novel anti-inflammatory mechanism in this large and well-defined patient population," he added.
Furthermore, patients with non-ischemic heart failure were 26 per cent less at risk of death or suffering a first cardiovascular hospitalisation when treated with Celacade.
The results were presented to the World Congress of Cardiology in Barcelona.
© Adfero Ltd
